Rigel shares slide after another drug flops in PhII asthma study

John Carroll Shares of Rigel Pharmaceuticals took a dive this morning, dropping 17% after the South San Francisco-based biotech announced that it is burying a program for allergic asthma ...

Bristol-Myers buries another depression drug after PhII flops

John Carroll In a document filed with the SEC, AMRI said that BMS-820836–an investigational triple reuptake inhibitor in a pair of mid-stage studies for treatment-resistant depression–failed ...

FDA deals Novo Nordisk another setback for hemophilia therapy

Ryan McBride The FDA has delivered a second complete response to the Danish drugmaker for its recombinant Factor VIII therapy, BioCentury reported, citing unresolved findings at the ...

Upsized Intrexon IPO delivers another blockbuster success for billionaire Kirk

John Carroll FierceBiotech News

Novartis grabs lead IL-17 program as Ensemble adds another marquee deal

John Carroll FierceBiotech News

Medicines Patent Pool Strikes Yet Another Big Pharma Deal

esilverman In the latest victory for the Medicines Patent Pool, Roche has agreed to improve access to Valcyte, which his used to treat cytomegalovirus, or CMV, a viral infection ...

India pulls another patent, this time for GSK’s Tykerb

Eric Palmer India's Intellectual Property Appellate Board (IPAB) has pulled the patent that GlaxoSmithKline had for its breast cancer drug Tykerb, a salt form of lapatinib, while ...

Another Pharma Deal Spurred, In Part, By A Lower Irish Tax Rate

esilverman ANOTHER PHARMA DEAL SPURRED, IN PART, BY A LOWER IRISH TAX RATE For the second time in recent weeks, Ireland has figured prominently in an acquisition of one drugmaker by ...

FDA deals Merck another setback for anesthesia drug sugammadex

John Carroll FierceBiotech News

BioCryst’s failed flu drug gets another shot at FDA success

John Carroll Last fall BioCryst ($ BCRX) took a careful look at the interim data from a late-stage study of its flu drug peramivir i.v. and prepared to read the last rites for the ...

Roche scraps diabetes drug as pRED racks up another PhIII fiasco

John Carroll Once again, Roche's pRED group has a big Phase III snafu to answer for. The Basel-based R&D side of the pharma giant–distinct from the gRED operations at ...

Ranbaxy, Another Bad FDA Report & The Missing Generic Diovan

esilverman Once again, Ranbaxy Laboratories may be facing a showdown with the FDA. The troubled generic drugmaker, which only recently agreed to pay $ 500 million to the US ...
Page 5 of 7« First...34567
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS